Helen M. Thackray, VP Clinical Development, CMO at GLYCOMIMETICS INC (GLYC), sold 22,000 shares at $7.40 ($154K) on 2016-07-01, disclosed to the SEC on 2016-07-06.
Open-market sale of $154k GLYC by VP Clinical Development, CMO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.40 | 5,068 | $38K | 24.4% |
| 2 | $7.01 | 10,136 | $71K | 46.2% |
| 3 | $6.68 | 6,796 | $45K | 29.5% |
| Total | $7.00 avg | 22,000 | $154K | 100% |
| Filing → |
| BCRX | SELL | 2022-12-19 | $34K | — | Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |